Histabil 40 Tablet contains Bilastine 40 mg, a second-generation antihistamine indicated for the symptomatic treatment of allergic conditions such as seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria. Bilastine selectively antagonizes peripheral H1 histamine receptors, thereby inhibiting the effects of histamine responsible for allergy symptoms including nasal congestion, sneezing, rhinorrhea, and pruritus. Its high specificity for H1 receptors minimizes sedative effects commonly associated with first-generation antihistamines, allowing for improved patient tolerability and safety. Histabil 40 is administered orally, with a recommended dosage of one tablet daily, providing effective 24-hour relief without significant central nervous system depression. The pharmacokinetic profile of Bilastine demonstrates rapid absorption, minimal metabolism, and predominant renal excretion, reducing the risk of drug interactions. It is contraindicated in patients with known hypersensitivity to Bilastine or any tablet excipients. Caution is advised in patients with severe renal impairment. Histabil 40 is not recommended for use in pediatric patients under 12 years without medical supervision. Overall, Histabil 40 offers a well-tolerated, efficacious option for managing allergic symptoms, enhancing patient quality of life through targeted histamine receptor blockade with a favorable safety profile.